Floatz logo

pf-08634404

Digestive System Disorder

PfizerUNKNOWNPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Digestive System Disorder cohort.

Asset / SponsorPhaseRating
Empagliflozin
Yonsei University
Phase 4BB
Marcaine
Cedars-Sinai Medical Center
Phase 4BB
Epinephrine
Cedars-Sinai Medical Center
Phase 4BB
Capecitabine
Zhejiang University
Phase 2BB
Pioglitazone
Yonsei University
Phase 4BB

View all 37 →

Same molecule, other indications

pf-08634404 is also rated in:

non-small cell lung carcinomaActive
BB
Indicative · Phase 3
66 / 100
View asset →
intestinal neoplasmActive
B
Indicative · Phase 3
60 / 100
View asset →
neoplasmActive
B
Indicative · Phase 3
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →